...
首页> 外文期刊>Drugs of the Future >Ceralasertib ATR kinase inhibitor Treatment of cancer
【24h】

Ceralasertib ATR kinase inhibitor Treatment of cancer

机译:Ceralasertib ATR激酶抑制剂治疗癌症

获取原文
获取原文并翻译 | 示例
           

摘要

Signaling through the serine/threonine kinase ataxia telangiectasia and Rad3 related (ATR) is necessary for identifying DNA damage and is an important cell cycle checkpoint during DNA replication and mitosis. Ceralasertib (AZD-6738) is an orally bioavailable, specific inhibitor of ATR. Pharmacokinetic studies of AZD-6738 have not reported interactions with other evaluated chemotherapies, including olaparib and durvalumab, supporting potential combination therapies. AZD-6738 may have antitumor activity through a number of mechanisms based on preclinical models, including increasing the activity of other chemotherapies by inhibiting the DNA damage response, augmenting an antitumor immune response, and by exploiting synthetically lethal pathways in the tumor cells including ATM-mutated or splicing factor-mutated cancers. Preliminary clinical experience shows that AZD-6738 is generally tolerable with primary toxicities including dose-dependent thrombocytopenia and mono-cytopenia. To date, several responses to AZD-6738, both as monotherapy and in therapy combinations, have been reported in patients with advanced solid tumors.
机译:通过丝氨酸/苏氨酸激酶共济失调和RAD3相关(ATR)的信号传导是鉴定DNA损伤的必要条件,并且是DNA复制和有丝分裂期间的重要细胞周期检查点。 Ceralasertib(AZD-6738)是口服生物的特异性抑制剂。 AZD-6738的药代动力学研究没有报道与其他评估化学疗法的相互作用,包括奥拉帕里布和Durvalumab,支持潜在的组合疗法。 AZD-6738可以通过基于临床前模型的许多机制具有抗肿瘤活性,包括通过抑制DNA损伤反应来增加其他化学疗法的活性,增强抗肿瘤免疫应答,并通过在包括ATM的肿瘤细胞中剥削合成致命的致命途径。突变或剪接因子突变的癌症。初步临床经验表明,AZD-6738通常具有初级毒性,包括剂量依赖性血小板减少和单胞嘧啶。迄今为止,已经报道了先进的实体肿瘤患者对AZD-6738作为单药治疗和治疗组合的几种反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号